A start-up should always have a “plan B” to provide a critical safety net. A considerable and expensive amount of redundant lab equipment can sit idle if that pivot arises and prompts a significant ...
Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIAtm and ZYNTEGLOtm in the U.S. has been selected for oral ...
“The rapid expansion of PCR-based testing for both infectious and genetic diseases ... Many laboratories are hesitant to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback